CEACAM6 and breast carcinoma: Drug sensitivity analysis using the oncoPredict package revealed that high expression of CEACAM6 was associated with increased predicted IC50 values for several commonly used chemotherapeutic and endocrine agents in HR+/HER2− breast cancer.